CYCN
- Cyclerion Therapeutics, Inc.
()
Overview
Company Summary
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies targeting serious and underserved diseases of the central nervous system (CNS). They focus on discovering and developing breakthrough treatments for conditions such as neurological disorders, including Alzheimer's disease, Parkinson's disease, and other related cognitive impairments.
The company employs a scientific approach called soluble guanylate cyclase (sGC) pharmacology to develop potentially transformative therapeutics for CNS diseases. This approach involves targeting the sGC enzyme, which plays a crucial role in regulating various biological pathways within the brain.
Cyclerion Therapeutics leverages its expertise in sGC pharmacology and drug discovery to identify and develop novel small molecule compounds that can modulate the sGC enzyme. By harnessing the potential of this pathway, they aim to address the pathological mechanisms underlying CNS diseases and potentially slow down disease progression or provide significant symptomatic relief.
In addition to their research and development efforts, Cyclerion Therapeutics also collaborates with academic institutions, pharmaceutical companies, and other external partners to leverage scientific expertise and accelerate the discovery and development of new treatments.
Overall, Cyclerion Therapeutics, Inc. is dedicated to advancing the field of CNS therapeutics by developing innovative solutions to address significant unmet medical needs in devastating neurological disorders.